France's DBV Technologies Q1 net loss widens on higher expenses

DBV Technologies SA

30/04/2026 21:49

Overview

France biopharma firm posted wider Q1 net loss as R&D and SG&A expenses increased

Company ended Q1 with $229 mln in cash, funding operations into Q2 2027

Increased spending reflects commercial launch preparations for VIASKIN Peanut Patch in U.S., if approved

Outlook

Company plans BLA submission for VIASKIN Peanut Patch in children aged 4-7 in H1 2026

DBV expects to submit BLA for VIASKIN Peanut Patch in toddlers aged 1-3 in H2 2026

Company says cash position expected to fund operations into Q2 2027

Result Drivers

R&D SPENDING - Higher R&D expenses driven by ongoing clinical studies and BLA-readiness activities for VIASKIN Peanut Patch

COMMERCIAL PREPARATION - Increased SG&A expenses reflect steps to build U.S. commercial infrastructure ahead of potential VIASKIN Peanut Patch launch

Company press release: ID:nGNEc4yxb5

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$47.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Dbv Technologies SA is €5.25, about 44.6% above its April 30 closing price of €3.63

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)